Arcadia Biosciences To Accelerate Agricultural Trait Development …Business Wire (press release)Arcadia Biosciences, Inc. (Nasdaq: RKDA), an agricultural technology company, announced today that it has signed a global licensing agreement with the.Arca… Continue reading
VarsityNew treatment gives second chance to leukemia patients at U of ChicagoThe Columbia ChronicleThe University of Chicago Medical Center is one of the first hospitals to offer a new cancer treatment that is giving late-stage leukemia and lymphoma pa… Continue reading
MedscapeImmunotherapy Changes First-Line Paradigm in Advanced RCCMedscapeNew data are set to change the paradigm for the first-line treatment of advanced renal cell carcinoma (RCC), after a phase 3 trial showed significantly improved overall survival (… Continue reading
MedscapeImmunotherapy Changes First-Line Paradigm in Advanced RCCMedscapeNew data are set to change the paradigm for the first-line treatment of advanced renal cell carcinoma (RCC), after a phase 3 trial showed significantly improved overall survival (… Continue reading
Mesothelioma Community Excited About First-Ever Gene Therapy Approval From FDAMesotheliomaHelp.org (blog)In July, MesotheliomaHelp reported on the pending approval of two different types of gene therapy for treating cancer and inherited diseases. Last … Continue reading
Renal and Urology NewsEarly NLR Changes Predict mRCC Immunotherapy OutcomesRenal and Urology NewsRises and decreases in neutrophil-to-lymphocyte ratio at 6 weeks after treatment with anti-PD-1/PD-L1 immune checkpoint blockade is associated with progres… Continue reading
Breakthrough made in stem cells scienceIndependent OnlineChicago – Two groups of scientists have successfully transformed human skin cells into stem cells, potentially granting unlimited access to the foundation cells which can replace diseased or dama… Continue reading
|
The investor euphoria for Incyte’s experimental cancer drug is hard to rationalize
STAT Depending on who you ask, the cancer immunotherapy accounts for $10 billion to $12 billion of Incyte’s current $27 billion market value. That’s a huge bet on a single drug not yet approved. If epacadostat were a stand-alone company, it would be worth … |